Acute coronary syndrome
Conditions
Interventions
experimental group:Suxiao Jiuxin Wan
control group:Suxiao Jiuxin Wan placebo
Sponsors
Guangdong Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Both acute coronary syndrome and qi stagnation and blood stasis syndrome met the diagnostic criteria; 2. Aged from 30 to 75 years; 3. Patients or their family members agreed to participate in the study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Permanent serious arrhythmia: III degree ATrioventricular block, sick sinus syndrome; 2. Cardiac arrest, cardiopulmonary resuscitation (CPR); 3. Severe heart failure: New York Heart Function Grade III-IV; 4. Acute cerebrovascular diseases (ischemic stroke, hemorrhagic stroke); 5. Severe diseases of blood system (hemophilia, severe anemia, thrombocytopenic purpura, primary thrombocytopenia); 6. Severe renal insufficiency; 7. Severe liver disease (liver cirrhosis or liver cancer), liver function damage (serum alanine aminotransferase/aspartate aminotransferase > 3 times the normal upper limit); 8. After gastrointestinal surgery, drug absorption may be affected; 9. Malignant tumors or life expectancy <= 2 years; 10. People with mental disorders or low intelligence; 11. Patients requiring coronary artery bypass graft (heart bypass graft); 13. Patients with severe respiratory diseases, such as severe chronic obstructive pulmonary disease, severe pulmonary hypertension and pulmonary embolism; 14. Women who are breastfeeding or pregnant, or women of childbearing age who plan to have a pregnancy within 6 months after screening, or who have a positive urine pregnancy test; Or male patients with fertility or sperm donation plans; 15. Suspected or confirmed history of alcohol or drug abuse; 16. Screening of patients who have participated in clinical trials of other drugs in the 3 months prior to the examination; 17. Other patients considered unsuitable for the study by the investigator; 18. Long-term oral anticoagulants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| endothelium dependent dilation; | — |
Secondary
| Measure | Time frame |
|---|---|
| endothelium independent dilation; | — |
Countries
China
Contacts
Public ContactChen Bojun
Guangdong Hospital of Traditional Chinese Medicine
Outcome results
None listed